EBITDA margin společnosti Abeona Therapeutics Inc
Jaká je hodnota metriky EBITDA margin společnosti Abeona Therapeutics Inc?
Hodnota metriky EBITDA margin společnosti Abeona Therapeutics Inc je -977.33%
Jaká je definice metriky EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Abeona Therapeutics Inc
Čemu se věnuje společnost Abeona Therapeutics Inc?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Firmy s metrikou ebitda margin podobnou společnosti Abeona Therapeutics Inc
- Hodnota metriky EBITDA margin společnosti Adrabbit je -1,007.72%
- Hodnota metriky EBITDA margin společnosti Oventus Medical je -1,005.03%
- Hodnota metriky EBITDA margin společnosti Wins Finance je -997.38%
- Hodnota metriky EBITDA margin společnosti Kairos Minerals je -995.30%
- Hodnota metriky EBITDA margin společnosti Linius Technologies je -985.68%
- Hodnota metriky EBITDA margin společnosti Aruma Resources je -979.66%
- Hodnota metriky EBITDA margin společnosti Abeona Therapeutics Inc je -977.33%
- Hodnota metriky EBITDA margin společnosti Abivax SA je -977.30%
- Hodnota metriky EBITDA margin společnosti Anterix je -976.00%
- Hodnota metriky EBITDA margin společnosti Concert Pharmaceuticals Inc je -975.28%
- Hodnota metriky EBITDA margin společnosti Pilot je -971.94%
- Hodnota metriky EBITDA margin společnosti De Grey Mining je -969.24%
- Hodnota metriky EBITDA margin společnosti Willow Biosciences je -968.55%